Osteoporosis medications fall into two broad families. Antiresorptive drugs slow the cells that break bone down; anabolic (bone-building) drugs stimulate new bone formation. Antiresorptives include oral and intravenous bisphosphonates, the injectable antibody denosumab, and the SERM raloxifene. Anabolic agents include teriparatide, abaloparatide, and romosozumab. Estrogen-based hormone therapy can also protect bone around menopause. Which option fits depends on your fracture risk, bone-density results, other health conditions, and preferences — so treat the list below as choices your clinician may discuss and individualize, not a ranked winner.
How the options compare at a glance
The matrix below summarizes the main treatment classes. It uses general routes and dosing frequency rather than specific doses, and every entry is a starting point for a conversation, not advice to begin, stop, or switch anything.
| Option | How it works | Best suited for | Route or frequency (general) | Key cautions |
|---|---|---|---|---|
| Oral bisphosphonates (e.g. alendronate, risedronate) | Antiresorptive — slows the osteoclasts that break down bone, helping preserve density. | Often the first option clinicians consider for postmenopausal osteoporosis at moderate risk; well studied and low cost. | Oral tablet, typically taken weekly or monthly on an empty stomach with water, staying upright afterward. | Can irritate the esophagus; rare jaw and atypical thigh-bone problems with long use; not suited to significant kidney impairment. |
| IV bisphosphonate (zoledronic acid) | Antiresorptive — the same bisphosphonate mechanism, delivered into a vein. | People who cannot tolerate or absorb oral tablets, or who prefer infrequent dosing. | Intravenous infusion, generally once a year in a clinic. | Flu-like symptoms may follow the first infusion; kidney function and calcium/vitamin D are checked beforehand. |
| Denosumab | Antiresorptive — an antibody that blocks RANKL, a signal osteoclasts need, reducing bone breakdown. | Higher fracture risk, reduced kidney function, or when bisphosphonates are not suitable. | Injection under the skin, usually every six months. | The effect can rebound quickly if stopped without a follow-on plan, so continuity matters; low calcium is corrected first. |
| Raloxifene (a SERM) | Antiresorptive — acts like estrogen on bone to slow loss while blocking estrogen effects elsewhere. | Postmenopausal women with mainly spine-related risk, or who want breast-risk considerations discussed. | Oral tablet, taken once daily. | Raises blood-clot risk and can worsen hot flashes; mainly reduces spine, not hip, fractures. |
| Teriparatide / abaloparatide | Anabolic — stimulates new bone formation through the parathyroid-hormone pathway. | High or very-high fracture risk, severe osteoporosis, or when antiresorptives have not been enough. | Daily self-injection under the skin, for a limited course (generally up to two years). | Time-limited; usually followed by an antiresorptive to preserve gains; avoided with certain bone conditions or prior skeletal radiation. |
| Romosozumab | Dual action — builds bone and modestly slows resorption by blocking sclerostin. | Very-high fracture risk in postmenopausal women. | Injection, generally monthly for up to one year, then followed by another agent. | Time-limited; a boxed warning about possible heart attack or stroke means cardiovascular history is weighed carefully. |
| Estrogen / hormone therapy (HRT) | Antiresorptive — replaces estrogen that normally restrains bone breakdown after menopause. | Around menopause, especially when hot flashes also need treatment; timing and personal risk matter. | Pill, patch, gel, or spray; a progestogen is added when the uterus is present. | Individualized benefit-risk (clots, stroke, breast considerations); often not chosen for bone alone when other options fit better. |
Antiresorptive vs anabolic: the core split
Most treatment plans open with an antiresorptive because these drugs are well studied, effective at cutting fracture risk, and often inexpensive. Anabolic agents — teriparatide, abaloparatide, and romosozumab — are typically reserved for high or very-high fracture risk, severe osteoporosis, or situations where an antiresorptive has not been enough. Because anabolic courses are time-limited, clinicians usually plan to follow them with an antiresorptive so newly built bone is preserved. Laying classes out this way mirrors how we structure our menopause treatment options comparison and the wider bone-health guides.
Where estrogen and HRT fit
Estrogen normally restrains bone breakdown, so the drop at menopause accelerates bone loss — one reason density can fall quickly in the first years after your last period. Hormone therapy can slow that loss, and some clinicians raise it as an option when bothersome symptoms such as hot flashes also need treatment. The decision is individualized against clot, stroke, and breast considerations and depends on timing and personal history. Our overviews of hormone replacement therapy and estrogen-only vs combined HRT, plus the broader menopause hub, explain the trade-offs your clinician weighs.
Foundations every plan shares
No medication works in isolation. Adequate calcium and vitamin D, weight-bearing and muscle-strengthening exercise, not smoking, and moderating alcohol underpin every option — guidance echoed by the NHS and the U.S. bone and endocrine societies. Bone density is usually tracked over time with a DEXA scan, and fracture risk is often estimated with a validated calculator before and during treatment. If you are weighing testing choices, see DEXA scan vs at-home bone test, and you can explore your risk factors with our bone-fracture-risk tool.
Bringing it to your clinician
A useful conversation usually covers your fracture risk and DEXA results, kidney function, any history of blood clots or cardiovascular disease, how you feel about tablets versus injections, and cost. To organize your questions, our menopause doctor-report tool can help you capture symptoms and history before the visit.
This guide is educational and general; it is not a recommendation to start, stop, or change any treatment. Osteoporosis care is highly individual, so talk to your clinician about which of these options — and which foundations of calcium, vitamin D, and monitoring — make sense for your bones, your risk, and your goals.
